SG11201906895WA - Rna cancer vaccines - Google Patents
Rna cancer vaccinesInfo
- Publication number
- SG11201906895WA SG11201906895WA SG11201906895WA SG11201906895WA SG11201906895WA SG 11201906895W A SG11201906895W A SG 11201906895WA SG 11201906895W A SG11201906895W A SG 11201906895WA SG 11201906895W A SG11201906895W A SG 11201906895WA SG 11201906895W A SG11201906895W A SG 11201906895WA
- Authority
- SG
- Singapore
- Prior art keywords
- epitopes
- international
- rna
- vaccines
- flank
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title abstract 3
- 238000009566 cancer vaccine Methods 0.000 title abstract 3
- 229920002477 rna polymer Polymers 0.000 abstract 6
- 108020004999 messenger RNA Proteins 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010069755 K-ras gene mutation Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010043376 Tetanus Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 206010013023 diphtheria Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4253—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453444P | 2017-02-01 | 2017-02-01 | |
| US201762453465P | 2017-02-01 | 2017-02-01 | |
| US201762558238P | 2017-09-13 | 2017-09-13 | |
| PCT/US2017/058595 WO2018144082A1 (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906895WA true SG11201906895WA (en) | 2019-08-27 |
Family
ID=63040027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906895WA SG11201906895WA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
| SG10202108307YA SG10202108307YA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202108307YA SG10202108307YA (en) | 2017-02-01 | 2017-10-26 | Rna cancer vaccines |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190351040A1 (enExample) |
| EP (1) | EP3576751A4 (enExample) |
| JP (2) | JP7731656B2 (enExample) |
| KR (2) | KR20240117650A (enExample) |
| CN (1) | CN110505877A (enExample) |
| AU (1) | AU2017397458B2 (enExample) |
| CA (1) | CA3052255A1 (enExample) |
| MA (1) | MA47401A (enExample) |
| RU (2) | RU2022106357A (enExample) |
| SG (2) | SG11201906895WA (enExample) |
| WO (1) | WO2018144082A1 (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| US11643441B1 (en) | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
| EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| EP3777881A1 (en) * | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| CA3052803A1 (en) * | 2017-02-07 | 2018-08-16 | Nantcell, Inc. | Maximizing t-cell memory and compositions and methods therefor |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| JP2021529750A (ja) * | 2018-06-27 | 2021-11-04 | モデルナティーエックス， インコーポレイテッド | 個別化がんワクチンエピトープの選択 |
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3866827A1 (en) | 2018-10-19 | 2021-08-25 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| JP2022506839A (ja) * | 2018-11-07 | 2022-01-17 | モデルナティエックス インコーポレイテッド | Ｒｎａがんワクチン |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR20210116525A (ko) * | 2019-01-14 | 2021-09-27 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| AU2020234003A1 (en) * | 2019-03-11 | 2021-11-11 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| JP7744829B2 (ja) * | 2019-03-25 | 2025-09-26 | オハイオ・ステイト・イノベーション・ファウンデーション | 組み合わせ免疫調節及びその使用 |
| WO2020242720A1 (en) * | 2019-05-02 | 2020-12-03 | University Of Florida Research Foundation, Inc. | Compositions for treatment of diffuse intrinsic pontine glioma |
| EP3976057A4 (en) * | 2019-05-31 | 2023-08-30 | ModernaTX, Inc. | EXPANDED T LYMPHOCYTE ASSAY |
| WO2020247914A1 (en) * | 2019-06-07 | 2020-12-10 | Emory University | Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto |
| CN110172480B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用 |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| US20220307017A1 (en) * | 2019-08-29 | 2022-09-29 | Universität Zürich | Minimal Messenger RNAs and uses thereof |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US20230002799A1 (en) * | 2019-12-11 | 2023-01-05 | Vanderbilt University | Methods of synthesizing mrna and functional proteins from synthetic double stranded dna |
| US20230130155A1 (en) * | 2020-01-30 | 2023-04-27 | Modernatx, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| JP2023512654A (ja) * | 2020-01-31 | 2023-03-28 | ジェネンテック， インコーポレイテッド | Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いてネオエピトープ特異的ｔ細胞を誘導する方法 |
| US20230096704A1 (en) * | 2020-02-05 | 2023-03-30 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| KR102701635B1 (ko) | 2020-03-11 | 2024-08-30 | 어드밴식스 레진즈 앤드 케미컬즈 엘엘씨 | 오일 및 가스 생산을 위한 계면활성제 |
| AU2021232924C1 (en) * | 2020-03-11 | 2025-07-24 | Advansix Resins & Chemicals Llc | Surfactants for healthcare products |
| JP2023522193A (ja) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 抗原プール |
| CA3174215A1 (en) | 2020-04-22 | 2021-10-28 | Ugur Sahin | Coronavirus vaccine |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| EP4175967A2 (en) | 2020-07-02 | 2023-05-10 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116322751A (zh) * | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP7644229B2 (ja) | 2020-10-20 | 2025-03-11 | エスティー ファーム カンパニー リミテッド | ５’－キャッピングされたｒｎａ合成用オリゴヌクレオチド |
| US20230391871A1 (en) * | 2020-10-22 | 2023-12-07 | The Regents Of The University Of California | Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams) |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| US20240299516A1 (en) * | 2020-12-21 | 2024-09-12 | University Of Florida Research Foundaton, Inc. | Multilamellar rna nanoparticle vaccine against cancer |
| CN114717229B (zh) * | 2021-01-05 | 2024-09-10 | 麦塞拿治疗(香港)有限公司 | 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CN117677389A (zh) * | 2021-03-26 | 2024-03-08 | 摩登纳特斯有限公司 | 百日咳疫苗 |
| NL2028681B1 (en) * | 2021-04-02 | 2022-10-17 | Nutcracker Therapeutics Inc | Materials and methods for generating antigen-specific t cells and treating diseases |
| CN113186285B (zh) * | 2021-05-10 | 2022-05-24 | 深圳市展行生物有限公司 | 一种辅助诊断胃癌的方法及其使用的miRNA组合 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| CN113577258B (zh) * | 2021-07-31 | 2024-04-16 | 山东兴瑞生物科技有限公司 | 一种双靶点mRNA疫苗及其制备方法 |
| CN115703714B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| WO2023030635A1 (en) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| EP4147712A1 (en) | 2021-09-13 | 2023-03-15 | OncoDNA | Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient |
| CA3230564A1 (en) | 2021-09-13 | 2023-03-16 | Jean-Pol DETIFFE | Method to generate personalized neoantigens of a tumor of a patient |
| EP4147713A1 (en) * | 2021-09-13 | 2023-03-15 | OncoDNA | A rna vaccine comprising an rna pool generated from a double-stranded dna pool |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4458843A4 (en) * | 2021-12-31 | 2025-07-09 | Guangzhou Nat Laboratory | MRNA VACCINE |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN119866224A (zh) * | 2022-07-28 | 2025-04-22 | 加拿大干细胞技术公司 | 编码连接抗原的多核苷酸以及其用途 |
| CN115992152A (zh) * | 2022-09-22 | 2023-04-21 | 浙江大学医学院附属第一医院 | 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用 |
| EP4600361A1 (en) * | 2022-10-07 | 2025-08-13 | University of Tsukuba | Design method and production method for nucleic acid construct and protein complex |
| WO2024086609A2 (en) * | 2022-10-19 | 2024-04-25 | Kalivir Immunotherapeutics, Inc. | Nucleic acids encoding soluble pd-1 and il-12 and uses thereof |
| EP4611918A1 (en) * | 2022-10-31 | 2025-09-10 | Gritstone bio, Inc. | Combination panel cell-free dna monitoring |
| WO2024097874A1 (en) * | 2022-11-03 | 2024-05-10 | Modernatx, Inc. | Chemical stability of mrna |
| EP4364752A1 (en) | 2022-11-07 | 2024-05-08 | OncoDNA | Improved vaccine |
| CN116970614A (zh) * | 2022-12-29 | 2023-10-31 | 达冕疫苗(广州)有限公司 | 编码ny-eso-1的核糖核酸疫苗的组合物和方法 |
| EP4651888A1 (en) * | 2023-01-17 | 2025-11-26 | The University Of Hong Kong | Cancer immunotherapy by delivery of mrna |
| CN119055671A (zh) * | 2023-05-23 | 2024-12-03 | 源生生物科技(青岛)有限责任公司 | 包含miRNA的活性成分及其应用 |
| WO2025054383A1 (en) * | 2023-09-06 | 2025-03-13 | Modernatx, Inc. | Chemical stability of mrna |
| WO2025080869A1 (en) * | 2023-10-11 | 2025-04-17 | The Regents Of The University Of California | Pancreatic cancer immunotherapy using cationic lipid and polymer nanocarriers for co-delivery of kras neoantigens and sting and/or other immunomodulators to boost the cancer immunity cycle and treat liver metastasis |
| WO2025117816A1 (en) * | 2023-12-01 | 2025-06-05 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025153053A1 (en) * | 2024-01-17 | 2025-07-24 | Abogen Biosciences (Shanghai) Co., Ltd. | Composition and methods for inducing antigen specific immunity against kras mutant cells |
| WO2025158069A1 (en) * | 2024-01-25 | 2025-07-31 | Rheinische Friedrich-Wilhelms-Universität Bonn | CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
| CN117883558B (zh) * | 2024-03-15 | 2024-06-14 | 山东兴瑞生物科技有限公司 | 靶向肝肿瘤个性化mRNA疫苗的制备方法 |
| CN119874872B (zh) * | 2025-01-17 | 2025-11-25 | 武汉大学 | 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| KR102017898B1 (ko) * | 2010-05-14 | 2019-09-04 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| LT3892295T (lt) * | 2011-05-24 | 2023-07-10 | BioNTech SE | Individualizuotos vakcinos nuo vėžio |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| KR101693090B1 (ko) * | 2011-08-16 | 2017-01-04 | 다이호야쿠힌고교 가부시키가이샤 | Kras 유전자 변이형의 결장 직장암 환자에 대한 항종양제 및 치료 효과 예측 방법 |
| EP2750707B1 (en) * | 2011-08-31 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Pegylated liposomes for delivery of immunogen-encoding rna |
| AU2013243954A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US10226528B2 (en) * | 2013-03-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines with biomolecular adjuvants |
| JP6558699B2 (ja) * | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| WO2016011226A1 (en) * | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2016201377A1 (en) * | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017070618A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
| KR20190086681A (ko) * | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 |
-
2017
- 2017-10-26 AU AU2017397458A patent/AU2017397458B2/en active Active
- 2017-10-26 RU RU2022106357A patent/RU2022106357A/ru unknown
- 2017-10-26 CN CN201780089255.1A patent/CN110505877A/zh active Pending
- 2017-10-26 SG SG11201906895WA patent/SG11201906895WA/en unknown
- 2017-10-26 KR KR1020247024776A patent/KR20240117650A/ko not_active Ceased
- 2017-10-26 CA CA3052255A patent/CA3052255A1/en active Pending
- 2017-10-26 JP JP2019541415A patent/JP7731656B2/ja active Active
- 2017-10-26 EP EP17894869.1A patent/EP3576751A4/en active Pending
- 2017-10-26 US US16/482,844 patent/US20190351040A1/en active Pending
- 2017-10-26 KR KR1020197025539A patent/KR20190120233A/ko not_active Ceased
- 2017-10-26 MA MA047401A patent/MA47401A/fr unknown
- 2017-10-26 RU RU2019127381A patent/RU2768829C2/ru active
- 2017-10-26 WO PCT/US2017/058595 patent/WO2018144082A1/en not_active Ceased
- 2017-10-26 SG SG10202108307YA patent/SG10202108307YA/en unknown
-
2023
- 2023-09-08 JP JP2023146197A patent/JP2023164537A/ja active Pending
-
2024
- 2024-08-16 US US18/807,315 patent/US20250134978A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ755780A (en) | 2023-10-27 |
| EP3576751A4 (en) | 2021-08-04 |
| SG10202108307YA (en) | 2021-08-30 |
| KR20240117650A (ko) | 2024-08-01 |
| WO2018144082A1 (en) | 2018-08-09 |
| KR20190120233A (ko) | 2019-10-23 |
| AU2017397458B2 (en) | 2025-07-10 |
| RU2019127381A3 (enExample) | 2021-06-17 |
| CN110505877A (zh) | 2019-11-26 |
| CA3052255A1 (en) | 2018-08-09 |
| US20250134978A1 (en) | 2025-05-01 |
| RU2768829C2 (ru) | 2022-03-24 |
| MA47401A (fr) | 2021-05-05 |
| JP7731656B2 (ja) | 2025-09-01 |
| AU2017397458A1 (en) | 2019-08-15 |
| JP2023164537A (ja) | 2023-11-10 |
| JP2020506189A (ja) | 2020-02-27 |
| RU2022106357A (ru) | 2022-03-24 |
| US20190351040A1 (en) | 2019-11-21 |
| EP3576751A1 (en) | 2019-12-11 |
| RU2019127381A (ru) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906895WA (en) | Rna cancer vaccines | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201910101SA (en) | Alphavirus neoantigen vectors | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201808474YA (en) | Method and system for desychronization recovery for permissioned blockchains using bloom filters | |
| SG11201903407XA (en) | Secretable variant immunomodulatory proteins and engineered cell therapy | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201809144XA (en) | Materials and methods for treatment of hemoglobinopathies | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201806400XA (en) | Replicative transposon system | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201804888WA (en) | Velocity model update with an inversion gradient | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy |